TY - JOUR
T1 - Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer
AU - Yahata, Hideaki
AU - Kodama, Keisuke
AU - Kaoru, Okugawa
AU - Hachisuga, Kazuhisa
AU - yasutake, nobuko
AU - Maenohara, Shoji
AU - Yagi, Hiroshi
AU - Yasunaga, Masafumi
AU - Ogami, Tatsuhiro
AU - Onoyama, Ichiro
AU - Asanoma, Kazuo
AU - Kobayashi, Hiroaki
AU - Sonoda, Kenzo
AU - Baba, Shingo
AU - Ishigami, Kousei
AU - Ohishi, Yoshihiro
AU - Oda, Yoshinao
AU - Kato, Kiyoko
N1 - Funding Information:
This study was supported in part by a grant-in-aid for scientific research (C) from the Japan Society for the Promotion of Science (Number JP19K09804 ).
Publisher Copyright:
© 2022
PY - 2022/4
Y1 - 2022/4
N2 - Objective: Sentinel node biopsy alone (SNB) reduces the postoperative complications of pelvic lymphadenectomy, such as lymphedema and lymphangitis; however, the long-term prognosis after SNB is unclear. The objective of this study was to evaluate the long-term outcome and complications of patients with early-stage cervical cancer who underwent SNB for hysterectomy or trachelectomy. Methods: We performed SNB for cervical cancer using a radioisotope method in 181 patients between 2009 and 2017. If the intraoperative sentinel lymph node evaluation was negative for metastasis, no further lymph nodes were removed. Results: The median age of the patients was 34 years (range, 21–73 years). The International Federation of Gynecology and Obstetrics 2008 stage was IA1 in 6 patients, IA2 in 18, IB1 in 154, and IIA1 in 3. Of the 181 patients (44 with hysterectomy, 137 with trachelectomy), 8 did not undergo pelvic lymphadenectomy because of a false-negative intraoperative diagnosis, 20 received adjuvant therapy after surgery, and 4 (2.2%) experienced recurrence over a median follow-up period of 83.5 months (range, 25–145 months). In the four recurrent cases, recurrence occurred in the pelvis, lung, and bone in one patient each, while the remaining patient developed pelvic and para-aortic lymph node metastases. Of these four patients, one died, and the remaining three are alive without disease after multidisciplinary therapy. The 5-year progression-free and overall survival rates were 98.8% and 99.4%, respectively. Postoperative complications, such as lymphedema, were very low rate. Conclusions: SNB for early-stage cervical cancer might be safe and effective, with no increase in the recurrence and postoperative complications rate.
AB - Objective: Sentinel node biopsy alone (SNB) reduces the postoperative complications of pelvic lymphadenectomy, such as lymphedema and lymphangitis; however, the long-term prognosis after SNB is unclear. The objective of this study was to evaluate the long-term outcome and complications of patients with early-stage cervical cancer who underwent SNB for hysterectomy or trachelectomy. Methods: We performed SNB for cervical cancer using a radioisotope method in 181 patients between 2009 and 2017. If the intraoperative sentinel lymph node evaluation was negative for metastasis, no further lymph nodes were removed. Results: The median age of the patients was 34 years (range, 21–73 years). The International Federation of Gynecology and Obstetrics 2008 stage was IA1 in 6 patients, IA2 in 18, IB1 in 154, and IIA1 in 3. Of the 181 patients (44 with hysterectomy, 137 with trachelectomy), 8 did not undergo pelvic lymphadenectomy because of a false-negative intraoperative diagnosis, 20 received adjuvant therapy after surgery, and 4 (2.2%) experienced recurrence over a median follow-up period of 83.5 months (range, 25–145 months). In the four recurrent cases, recurrence occurred in the pelvis, lung, and bone in one patient each, while the remaining patient developed pelvic and para-aortic lymph node metastases. Of these four patients, one died, and the remaining three are alive without disease after multidisciplinary therapy. The 5-year progression-free and overall survival rates were 98.8% and 99.4%, respectively. Postoperative complications, such as lymphedema, were very low rate. Conclusions: SNB for early-stage cervical cancer might be safe and effective, with no increase in the recurrence and postoperative complications rate.
UR - http://www.scopus.com/inward/record.url?scp=85124423933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124423933&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2022.01.031
DO - 10.1016/j.ygyno.2022.01.031
M3 - Article
C2 - 35151491
AN - SCOPUS:85124423933
SN - 0090-8258
VL - 165
SP - 149
EP - 154
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -